Likelihood of Approval and Phase Transition Success Rate Model – Coronavirus Disease 2019 (COVID-19) vaccine
Overview
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models.
Likelihood of Approval (LoA) – Industry
Coronavirus Disease 2019 (COVID-19) vaccine Drug Details
Coronavirus Disease 2019 (COVID-19) vaccine (CoronaVac) is an inactivated whole virion vaccine composed of inactivated SARS-CoV-2 virus antigen. It is manufactured in a Vero cell manufacturing platform. It is formulated as suspension for intramuscular route of administration. CoronaVac is indicated for the prevention of coronavirus disease 2019 (COVID-19) in individuals aged 3 years and above. coronaVac is indicated for the prevention of Coronavirus Disease 2019 (COVID-19) in patients aged 18 and above adults. CoronaVac is indicated for the prevention of Coronavirus Disease in children 3 years to 5 years of age. Picovacc is under development for the prevention of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is an inactivated vaccine. It is administered through intramuscular route.
Report Coverage
The data is segmented by drug name and intervention type and shows the current likelihood of approval for the drug compared to both the indication benchmark and the industry benchmark so you can:
- Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
- Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
- Use PTSR and LOA information and event-driven changes for your investment decisions to generate alpha
Additionally, this data is updated regularly based on events that take place which impact the clinical development process. GlobalData uses its proprietary machine learning models to track event-driven changes in LOA and PTSR and provides the quantitative changes to the likelihood of success along with the qualitative reasoning why the likelihood of approval has changed.
| Quick View – LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas | |||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Allows clients to track and predict specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
- Obtain information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
- Track event-driven changes in LOA and PTSR benchmarked against indication and industry values
- Use PTSR and LOA information and event driven changes for your investment decisions to generate alpha
Key Players
Frequently Asked Questions
The probability of a drug ultimately receiving market authorization
The probability of a drug’s advancement to the next stage of clinical development
GlobalData’s Drug-Specific Likelihood of Approval (LoA) calculates the Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases.
Inclusion
Data Scope:
- Drugs which have been approved in the past 10 years
- Drugs which have failed during clinical development in the past 18 years
- Drugs which are currently in development
Drug Phase Scope:
- Phase I, Phase II, Phase III, and Pre-Registration development stage
Drug Geography Scope:
- Drugs must meet one of the following criteria to be included in the model:
- The developer has specified the US as an intended market for approval.
- The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”
Drug Type Scope:
- Innovator drugs and biosimilars
Entity Type Scope:
Only drugs in development by companies are included in the model.
Exclusion
- Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
- Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
- Generic drugs
- Innovative drugs in Preclinical or Discovery Stage.
- Pipeline drugs sponsored by a Government or Institution.
- Drugs with a specific Drug Geography not the United States.
Methodology
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Pharmaceuticals reports